<i>Gaia</i> Data Release 1. Summary of the astrometric, photometric, and survey properties

Context. At about 1000 days after the launch of Gaia we present the first Gaia data release, Gaia DR1, consisting of astrometry and photometry for over 1 billion sources brighter than magnitude 20.7. Aims. A summary of Gaia DR1 is presented along with illustrations of the scientific quality of the data, followed by a discussion of the limitations due to the preliminary nature of this release. Methods. The raw data collected by Gaia during the first 14 months of the mission have been processed by the Gaia Data Processing and Analysis Consortium (DPAC) and turned into an astrometric and photometric catalogue. Results. Gaia DR1 consists of three components: a primary astrometric data set which contains the positions, parallaxes, and mean proper motions for about 2 million of the brightest stars in common with the HIPPARCOS and Tycho-2 catalogues – a realisation of the Tycho-Gaia Astrometric Solution (TGAS) – and a secondary astrometric data set containing the positions for an additional 1.1 billion sources. The second component is the photometric data set, consisting of mean G-band magnitudes for all sources. The G-band light curves and the characteristics of ∼3000 Cepheid and RR-Lyrae stars, observed at high cadence around the south ecliptic pole, form the third component. For the primary astrometric data set the typical uncertainty is about 0.3 mas for the positions and parallaxes, and about 1 mas yr−1 for the proper motions. A systematic component of ∼0.3 mas should be added to the parallax uncertainties. For the subset of ∼94 000 HIPPARCOS stars in the primary data set, the proper motions are much more precise at about 0.06 mas yr−1. For the secondary astrometric data set, the typical uncertainty of the positions is ∼10 mas. The median uncertainties on the mean G-band magnitudes range from the mmag level to ∼0.03 mag over the magnitude range 5 to 20.7. Conclusions. Gaia DR1 is an important milestone ahead of the next Gaia data release, which will feature five-parameter astrometry for all sources. Extensive validation shows that Gaia DR1 represents a major advance in the mapping of the heavens and the availability of basic stellar data that underpin observational astrophysics. Nevertheless, the very preliminary nature of this first Gaia data release does lead to a number of important limitations to the data quality which should be carefully considered before drawing conclusions from the data

Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART

BACKGROUND: Chronic hepatitis C is common and aggressive in HIV-positive patients, so the development of a well-tolerated HCV therapy is a priority. We evaluated the efficacy and safety of pegylated interferon alpha2b (PEG-IFN) plus ribavirin (RBV) versus PEG-IFN monotherapy in HIV/HCV-coinfected patients undergoing highly active antiretroviral therapy (HAART), and analysed the predictive factors of response. METHODS: An Italian, multicentre, open-label trial including 135 coinfected patients, randomized to PEG-IFN 1.5 microg/kg/week plus RBV 400 mg twice daily (n=69, arm A) or PEG-IFN 1.5 microg/kg/week (n=66, arm B) for 48 weeks. We assessed the predictive values of early virological response (EVR) at week 8 (HCV-RNA drop >2 log10 compared with baseline or undetectable levels) on sustained virological response (SVR). RESULTS: Fifty-five patients (28 from arm A and 27 from arm B) completed 48 weeks of therapy. At the end of treatment, 20/28 patients in arm A and 11/27 in arm B had HCV-RNA <50 IU/ml. In a per-protocol analysis, SVR was reached by 54% of patients in arm A (genotype 2-3, 11/16; genotype 1-4, 4/12) and 22% in arm B (genotype 2-3, 3/15; genotype 1-4, 3/12). In an intention-to-treat analysis, the SVR was 22% in arm A (genotype 2-3, 11/32; genotype 1-4, 4/37) versus 9% in arm B (genotype 2-3, 3/32; genotype 1-4, 3/34). The best predictors of SVR were the use of combination therapy, infection with HCV genotype 3 versus genotype 1, and EVR at week 8. Thirty patients (15 from arm A and 15 from arm B) dropped out of the trial prematurely due to side effects. The positive predictive value of EVR at week 8 was 65%, the negative predictive value was 86%. CONCLUSIONS: PEG-IFN plus RBV can be considered a solid option for the treatment of HIV/HCV-coinfected patients. The key to successfully improving efficacy is strong compliance through strict overall patient monitoring, in order to best manage drug toxicity. EVR assessment at week 8 may become a useful stategy in the management of therapy

Albumin in decompensated cirrhosis: New concepts and perspectives

The pathophysiological background of decompensated cirrhosis is characterised by a systemic proinflammatory and pro-oxidant milieu that plays a major role in the development of multiorgan dysfunction. Such abnormality is mainly due to the systemic spread of bacteria and/or bacterial products from the gut and danger-associated molecular patterns from the diseased liver triggering the release of proinflammatory mediators by activating immune cells. The exacerbation of these processes underlies the development of acute-on-chronic liver failure. A further mechanism promoting multiorgan dysfunction and failure likely consists with a mitochondrial oxidative phosphorylation dysfunction responsible for systemic cellular energy crisis. The systemic proinflammatory and pro-oxidant state of patients with decompensated cirrhosis is also responsible for structural and functional changes in the albumin molecule, which spoil its pleiotropic non-oncotic properties such as antioxidant, scavenging, immune-modulating and endothelium protective functions. The knowledge of these abnormalities provides novel targets for mechanistic treatments. In this respect, the oncotic and non-oncotic properties of albumin make it a potential multitarget agent. This would expand the well-established indications to the use of albumin in decompensated cirrhosis, which mainly aim at improving effective volaemia or preventing its deterioration. Evidence has been recently provided that long-term albumin administration to patients with cirrhosis and ascites improves survival, prevents complications, eases the management of ascites and reduces hospitalisations. However, variant results indicate that further investigations are needed, aiming at confirming the beneficial effects of albumin, clarifying its optimal dosage and administration schedule and identify patients who would benefit most from long-term albumin administration

Gaia Data Release 3: analysis of the Gaia BP/RP spectra using the General Stellar Parameterizer from Photometry

Context. The astrophysical characterisation of sources is among the major new data products in the third Gaia Data Release (DR3). In particular, there are stellar parameters for 471 million sources estimated from low-resolution BP/RP spectra. Aims. We present the General Stellar Parameterizer from Photometry (GSP-Phot), which is part of the astrophysical parameters inference system (Apsis). GSP-Phot is designed to produce a homogeneous catalogue of parameters for hundreds of millions of single non-variable stars based on their astrometry, photometry, and low-resolution BP/RP spectra. These parameters are effective temperature, surface gravity, metallicity, absolute MG magnitude, radius, distance, and extinction for each star. Methods. GSP-Phot uses a Bayesian forward-modelling approach to simultaneously fit the BP/RP spectrum, parallax, and apparent G magnitude. A major design feature of GSP-Phot is the use of the apparent flux levels of BP/RP spectra to derive, in combination with isochrone models, tight observational constraints on radii and distances. We carefully validate the uncertainty estimates by exploiting repeat Gaia observations of the same source. Results. The data release includes GSP-Phot results for 471 million sources with G   20), mostly within 2 kpc. Metallicity estimates exhibit substantial biases compared to literature values and are only useful at a qualitative level. However, we provide an empirical calibration of our metallicity estimates that largely removes these biases. Extinctions A0 and ABP show typical differences from reference values of 0.07–0.09 mag. MCMC samples of the parameters are also available for 95% of the sources. Conclusions. GSP-Phot provides a homogeneous catalogue of stellar parameters, distances, and extinctions that can be used for various purposes, such as sample selections (OB stars, red giants, solar analogues etc.). In the context of asteroseismology or ground-based interferometry, where targets are usually bright and have good parallax measurements, GSP-Phot results should be particularly useful for combined analysis or target selection.This work presents results from the European Space Agency (ESA) space mission Gaia. Gaia data are being processed by the Gaia Data Processing and Analysis Consortium (DPAC). Funding for the DPAC is provided by national institutions, in particular the institutions participating in the Gaia MultiLateral Agreement (MLA). The Gaia mission website is https://www.cosmos.esa.int/gaia.The Gaia archive website is https://archives.esac.esa.int/gaia. The Gaia mission and data processing have financially been supported by, in alphabetical order by country: • the Algerian Centre de Recherche en Astronomie, Astrophysique et Géophysique of Bouzareah Observatory; • the Austrian Fonds zur Förderung der wissenschaftlichen Forschung (FWF) Hertha Firnberg Programme through grants T359, P20046, and P23737; • the BELgian federal Science Policy Office (BELSPO) through various PROgramme de Développement d’Expériences scientifiques (PRODEX) grants and the Polish Academy of Sciences - Fonds Wetenschappelijk Onderzoek through grant VS.091.16N, and the Fonds de la Recherche Scientifique (FNRS), and the Research Council of Katholieke Universiteit (KU) Leuven through grant C16/18/005 (Pushing AsteRoseismology to the next level with TESS, GaiA, and the Sloan DIgital Sky SurvEy – PARADISE); • the Brazil-France exchange programmes Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Coordenação de Aperfeicoamento de Pessoal de Nível Superior (CAPES) - Comité Français d’Evaluation de la Coopération Universitaire et Scientifique avec le Brésil (COFECUB); • the Chilean Agencia Nacional de Investigación y Desarrollo (ANID) through Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) Regular Project 1210992 (L. Chemin); • the National Natural Science Foundation of China (NSFC) through grants 11573054, 11703065, and 12173069, the China Scholarship Council through grant 201806040200, and the Natural Science Foundation of Shanghai through grant 21ZR1474100; • the Tenure Track Pilot Programme of the Croatian Science Foundation and the École Polytechnique Fédérale de Lausanne and the project TTP-2018-07-1171 ‘Mining the Variable Sky’, with the funds of the Croatian-Swiss Research Programme; • the Czech-Republic Ministry of Education, Youth, and Sports through grant LG 15010 and INTER-EXCELLENCE grant LTAUSA18093, and the Czech Space Office through ESA PECS contract 98058; • the Danish Ministry of Science; • the Estonian Ministry of Education and Research through grant IUT40-1; • the European Commission’s Sixth Framework Programme through the European Leadership in Space Astrometry (https://www.cosmos.esa.int/web/gaia/elsa-rtn-programme) Marie Curie Research Training Network (MRTN-CT-2006-033481), through Marie Curie project PIOF-GA-2009-255267 (Space AsteroSeismology & RR Lyrae stars, SAS-RRL), and through a Marie Curie Transfer-of-Knowledge (ToK) fellowship (MTKD-CT-2004-014188); the European Commission’s Seventh Framework Programme through grant FP7-606740 (FP7-SPACE-2013-1) for the Gaia European Network for Improved data User Services (https://gaia.ub.edu/twiki/do/view/GENIUS/) and through grant 264895 for the Gaia Research for European Astronomy Training (https://www.cosmos.esa.int/web/gaia/great-programme) network; • the European Cooperation in Science and Technology (COST) through COST Action CA18104 ‘Revealing the Milky Way with Gaia (MW-Gaia)’; • the European Research Council (ERC) through grants 320360, 647208, and 834148 and through the European Union’s Horizon 2020 research and innovation and excellent science programmes through Marie Skłodowska-Curie grant 745617 (Our Galaxy at full HD – Gal-HD) and 895174 (The build-up and fate of self-gravitating systems in the Universe) as well as grants 687378 (Small Bodies: Near and Far), 682115 (Using the Magellanic Clouds to Understand the Interaction of Galaxies), 695099 (A sub-percent distance scale from binaries and Cepheids – CepBin), 716155 (Structured ACCREtion Disks – SACCRED), 951549 (Sub-percent calibration of the extragalactic distance scale in the era of big surveys – UniverScale), and 101004214 (Innovative Scientific Data Exploration and Exploitation Applications for Space Sciences – EXPLORE); • the European Science Foundation (ESF), in the framework of the Gaia Research for European Astronomy Training Research Network Programme (https://www.cosmos.esa.int/web/gaia/great-programme); • the European Space Agency (ESA) in the framework of the Gaia project, through the Plan for European Cooperating States (PECS) programme through contracts C98090 and 4000106398/12/NL/KML for Hungary, through contract 4000115263/15/NL/IB for Germany, and through PROgramme de Développement d’Expériences scientifiques (PRODEX) grant 4000127986 for Slovenia; • the Academy of Finland through grants 299543, 307157, 325805, 328654, 336546, and 345115 and the Magnus Ehrnrooth Foundation; • the French Centre National d’Études Spatiales (CNES), the Agence Nationale de la Recherche (ANR) through grant ANR-10-IDEX-0001-02 for the ‘Investissements d’avenir’ programme, through grant ANR-15-CE31-0007 for project ‘Modelling the Milky Way in the Gaia era’ (MOD4Gaia), through grant ANR-14-CE33-0014-01 for project ‘The Milky Way disc formation in the Gaia era’ (ARCHEOGAL), through grant ANR-15-CE31-0012-01 for project ‘Unlocking the potential of Cepheids as primary distance calibrators’ (UnlockCepheids), through grant ANR-19-CE31-0017 for project ‘Secular evolution of galxies’ (SEGAL), and through grant ANR-18-CE31-0006 for project ‘Galactic Dark Matter’ (GaDaMa), the Centre National de la Recherche Scientifique (CNRS) and its SNO Gaia of the Institut des Sciences de l’Univers (INSU), its Programmes Nationaux: Cosmologie et Galaxies (PNCG), Gravitation Références Astronomie Métrologie (PNGRAM), Planétologie (PNP), Physique et Chimie du Milieu Interstellaire (PCMI), and Physique Stellaire (PNPS), the ‘Action Fédératrice Gaia’ of the Observatoire de Paris, the Région de Franche-Comté, the Institut National Polytechnique (INP) and the Institut National de Physique nucléaire et de Physique des Particules (IN2P3) co-funded by CNES; • the German Aerospace Agency (Deutsches Zentrum für Luft- und Raumfahrt e.V., DLR) through grants 50QG0501, 50QG0601, 50QG0602, 50QG0701, 50QG0901, 50QG1001, 50QG1101, 50QG1401, 50QG1402, 50QG1403, 50QG1404, 50QG1904, 50QG2101, 50QG2102, and 50QG2202, and the Centre for Information Services and High Performance Computing (ZIH) at the Technische Universität Dresden for generous allocations of computer time; • the Hungarian Academy of Sciences through the Lendület Programme grants LP2014-17 and LP2018-7 and the Hungarian National Research, Development, and Innovation Office (NKFIH) through grant KKP-137523 (‘SeismoLab’); • the Science Foundation Ireland (SFI) through a Royal Society - SFI University Research Fellowship (M. Fraser); • the Israel Ministry of Science and Technology through grant 3-18143 and the Tel Aviv University Center for Artificial Intelligence and Data Science (TAD) through a grant; • the Agenzia Spaziale Italiana (ASI) through contracts I/037/08/0, I/058/10/0, 2014-025-R.0, 2014-025-R.1.2015, and 2018-24-HH.0 to the Italian Istituto Nazionale di Astrofisica (INAF), contract 2014-049-R.0/1/2 to INAF for the Space Science Data Centre (SSDC, formerly known as the ASI Science Data Center, ASDC), contracts I/008/10/0, 2013/030/I.0, 2013-030-I.0.1-2015, and 2016-17-I.0 to the Aerospace Logistics Technology Engineering Company (ALTEC S.p.A.), INAF, and the Italian Ministry of Education, University, and Research (Ministero dell’Istruzione, dell’Università e della Ricerca) through the Premiale project ‘MIning The Cosmos Big Data and Innovative Italian Technology for Frontier Astrophysics and Cosmology’ (MITiC); • the Netherlands Organisation for Scientific Research (NWO) through grant NWO-M-614.061.414, through a VICI grant (A. Helmi), and through a Spinoza prize (A. Helmi), and the Netherlands Research School for Astronomy (NOVA); • the Polish National Science Centre through HARMONIA grant 2018/30/M/ST9/00311 and DAINA grant 2017/27/L/ST9/03221 and the Ministry of Science and Higher Education (MNiSW) through grant DIR/WK/2018/12; • the Portuguese Fundação para a Ciência e a Tecnologia (FCT) through national funds, grants SFRH/BD/128840/2017 and PTDC/FIS-AST/30389/2017, and work contract DL 57/2016/CP1364/CT0006, the Fundo Europeu de Desenvolvimento Regional (FEDER) through grant POCI-01-0145-FEDER-030389 and its Programa Operacional Competitividade e Internacionalização (COMPETE2020) through grants UIDB/04434/2020 and UIDP/04434/2020, and the Strategic Programme UIDB/00099/2020 for the Centro de Astrofísica e Gravitação (CENTRA); • the Slovenian Research Agency through grant P1-0188; • the Spanish Ministry of Economy (MINECO/FEDER, UE), the Spanish Ministry of Science and Innovation (MICIN), the Spanish Ministry of Education, Culture, and Sports, and the Spanish Government through grants BES-2016-078499, BES-2017-083126, BES-C-2017-0085, ESP2016-80079-C2-1-R, ESP2016-80079-C2-2-R, FPU16/03827, PDC2021-121059-C22, RTI2018-095076-B-C22, and TIN2015-65316-P (‘Computación de Altas Prestaciones VII’), the Juan de la Cierva Incorporación Programme (FJCI-2015-2671 and IJC2019-04862-I for F. Anders), the Severo Ochoa Centre of Excellence Programme (SEV2015-0493), and MICIN/AEI/10.13039/501100011033 (and the European Union through European Regional Development Fund ‘A way of making Europe’) through grant RTI2018-095076-B-C21, the Institute of Cosmos Sciences University of Barcelona (ICCUB, Unidad de Excelencia ‘María de Maeztu’) through grant CEX2019-000918-M, the University of Barcelona’s official doctoral programme for the development of an R+D+i project through an Ajuts de Personal Investigador en Formació (APIF) grant, the Spanish Virtual Observatory through project AyA2017-84089, the Galician Regional Government, Xunta de Galicia, through grants ED431B-2021/36, ED481A-2019/155, and ED481A-2021/296, the Centro de Investigación en Tecnologías de la Información y las Comunicaciones (CITIC), funded by the Xunta de Galicia and the European Union (European Regional Development Fund – Galicia 2014-2020 Programme), through grant ED431G-2019/01, the Red Española de Supercomputación (RES) computer resources at MareNostrum, the Barcelona Supercomputing Centre - Centro Nacional de Supercomputación (BSC-CNS) through activities AECT-2017-2-0002, AECT-2017-3-0006, AECT-2018-1-0017, AECT-2018-2-0013, AECT-2018-3-0011, AECT-2019-1-0010, AECT-2019-2-0014, AECT-2019-3-0003, AECT-2020-1-0004, and DATA-2020-1-0010, the Departament d’Innovació, Universitats i Empresa de la Generalitat de Catalunya through grant 2014-SGR-1051 for project ‘Models de Programació i Entorns d’Execució Parallels’ (MPEXPAR), and Ramon y Cajal Fellowship RYC2018-025968-I funded by MICIN/AEI/10.13039/501100011033 and the European Science Foundation (‘Investing in your future’); • the Swedish National Space Agency (SNSA/Rymdstyrelsen); • the Swiss State Secretariat for Education, Research, and Innovation through the Swiss Activités Nationales Complémentaires and the Swiss National Science Foundation through an Eccellenza Professorial Fellowship (award PCEFP2_194638 for R. Anderson); • the United Kingdom Particle Physics and Astronomy Research Council (PPARC), the United Kingdom Science and Technology Facilities Council (STFC), and the United Kingdom Space Agency (UKSA) through the following grants to the University of Bristol, the University of Cambridge, the University of Edinburgh, the University of Leicester, the Mullard Space Sciences Laboratory of University College London, and the United Kingdom Rutherford Appleton Laboratory (RAL): PP/D006511/1, PP/D006546/1, PP/D006570/1, ST/I000852/1, ST/J005045/1, ST/K00056X/1, ST/K000209/1, ST/K000756/1, ST/L006561/1, ST/N000595/1, ST/N000641/1, ST/N000978/1, ST/N001117/1, ST/S000089/1, ST/S000976/1, ST/S000984/1, ST/S001123/1, ST/S001948/1, ST/S001980/1, ST/S002103/1, ST/V000969/1, ST/W002469/1, ST/W002493/1, ST/W002671/1, ST/W002809/1, and EP/V520342/1

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post_treatment hospitalisation status

SARS-CoV-2 is causing an increasing number of deaths worldwide because no effective treatment is currently available. Remdesivir has shown in vitro activity against coronaviruses and is a possible antiviral treatment for SARS-CoV-2 infection. This prospective (compassionate), open-label study of remdesivir, which was conducted at Luigi Sacco Hospital, Milan, Italy, between February 23 and March 20, 2020, involved patients with SARS-CoV-2 pneumonia aged 6518 years undergoing mechanical ventilation or with an oxygen saturation level of 6494% in air or a National Early Warning Score 2 of 654. The primary outcome was the change in clinical status based on a 7-category ordinal scale (1 = not hospitalised, resuming normal daily activities; 7 = deceased). The 35 patients enrolled from February 23 to March 20, 2020, included 18 in intensive care unit (ICU), and 17 in our infectious diseases ward (IDW). The 10-day course of remdesivir was completed by 22 patients (63%) and discontinued by 13, of whom eight (22.8%) discontinued because of adverse events. The median follow-up was 39 days (IQR 25-44). At day 28, 14 (82.3%) patients from IDW were discharged, two were still hospitalized and one died (5.9%), whereas in ICU 6 (33.3%) were discharged, 8 (44.4%) patients died, three (16.7%) were still mechanically ventilated and one (5.6%) was improved but still hospitalized. Hypertransaminasemia and acute kidney injury were the most frequent severe adverse events observed (42.8% and 22.8% of the cases, respectively). Our data suggest that remdesivir can benefit patients with SARS-CoV-2 pneumonia hospitalised outside ICU where clinical outcome was better and adverse events are less frequently observed. Ongoing randomised controlled trials will clarify its real efficacy and safety, who to treat, and when